![](https://investorshub.advfn.com/uicon/792403.png?cb=1632160976)
Wednesday, July 12, 2023 11:40:13 AM
Below is the DD, straight from the source, if you would like it.
https://www.otcmarkets.com/stock/ENZC/news/Virogentics-and-Enzolytics-Refute-Misleading-Information-Being-Circulated-on-Social-Media-and-Other-Internet-Outlets-Bio?id=401452
Virogentics, a subsidiary of Enzolytics, is the exclusive licensee for ITV-1 and the exclusive licensee in the U.S. and most world countries of IPF Immune.
Annual Report - DISCLOSURE FILING AND FINANCIALS 2022 OTC NEW FORMAT
https://www.otcmarkets.com/otcapi/company/financial-report/366963/content
On November 30, 2020, the Company consummated the Merger Agreement which involved the formation of two wholly-owned operating subsidiaries, Biogenysis, Inc., (“Biogenysis) and Virogentics, Inc., (“Virogentics”). Biogenysis was formed to acquire the intellectual property rights of and license owned by certain officers of BioClonetics Immunotherapeutics, Inc., (“BioClonetics”) and Virogentics which was formed to acquire the intellectual property rights of and licensed owned by a controlling stockholder of Enzolytics.
[...]
Following the business combination, the Company issued 204,430,000 shares of its Series B Convertible Preferred Stock to officers of BioClonetics who owned the intellectual property rights to the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, relating to NOVEL HIV- BINDING PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof. In addition, the Company issued 90,750,000 shares of its Series B Convertible Preferred Stock to the controlling stockholder of Enzolytics who owned the intellectual property rights to U.S. Patent No. 7,479538, entitled Irreversibly- Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV and U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof.
[...]
Effective December 1, 2020, the Company, through Bioclonetics, entered a lease with Texas A & M University for office and laboratory space on the campus of Texas A&M University in the University's Institute for Preclinical Studies in order to expand the Company’s development capabilities for the production of additional monoclonal antibodies.
https://www.otcmarkets.com/otcapi/company/financial-report/376167/content
Enzolytics, Inc. (OTC PINK: ENZC) (“ENZC” or “the “Company”) recently entered into a nonbinding letter of intent with Sagaliam Acquisition Corp. (“NASDAQ: SAGA”) (“SAGA”) (together the “Parties”) to sale its two operating subsidiaries Biogenysis, Inc. (“BGEN”) and Virogentics, Inc. (“VIRO”)
After the dividend to Company E shareholders, there would be no assets or operations in Company E, but management would be able to purchase new operations or develop other products that would be the assets of Company E. The Company E common shares would continue to trade on OTC Markets as a new business strategy is implemented.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Continues-Progress-with-Business-Combination-Biogenysis-Announces-Team-and-Plans-for-Success?id=398191
Dr. Gaurav Chandra has been appointed the Chief Executive Officer and Chairman of Biogenysis.
Mr. Cotropia will continue as the Executive Director of Biogenysis [...]
Dr. Joseph Cotropia will assume the Chief Scientific Officer position of Biogenysis [...]
Dr. Suraj Saggar will be an Advisory Board Member of Biogenysis [...]
Dr. Kirsten Bischof will continue to develop the AI platform as an Advisory Board Member. In addition, as the AI platform is expanded, Dr. Bischof will serve as the Chief Information Officer [...]
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM